Overview of Auget

Property	Description
Active ingredient	Amoxicillin, Clavulanic Acid (Co-amoxiclav)
Form	Tablet, Suspension, Injection
Pharmacological class	Penicillins / beta-lactamase Inhibitors
Common use	Anti-infective agent (combats bacterial growth)
Origin	Semi-synthetic

Identity and Pharmacological Classification

Auget is a brand name for the prescription medication officially known as Co-amoxiclav, which is the fixed-dose combination of Amoxicillin and Clavulanic Acid. This drug is classified as an antibacterial agent belonging to the penicillins / beta-lactamase inhibitors pharmacological group. The dual-component formulation is widely clinically recognized for its ability to overcome common bacterial resistance mechanisms.

Composition and Available Preparations

Auget is a semi-synthetic entity whose effectiveness relies on its two active ingredients: the antibiotic Amoxicillin and the enzyme inhibitor Clavulanic Acid (often as potassium salt). The Amoxicillin component is an aminopenicillin that targets bacterial cell structures. The addition of Clavulanic Acid serves a specific protective role, distinguishing this product from simpler penicillin formulations and demonstrating its necessity as a core anti-infective treatment.

The medication is prepared in multiple dosage forms, including the orally administered Film-Coated Tablet and a Powder for Oral Suspension, alongside preparations for Intravenous administration in clinical settings.

General Purpose of the Amoxicillin/Clavulanic Acid Combination

The general purpose of this specific formulation is to enhance the functional range of the antibiotic against resistance. The Clavulanic Acid component prevents the destruction of Amoxicillin by neutralizing the beta-lactamase enzymes produced by resistant bacteria. This synergistic action ensures the primary antibiotic remains functional to resolve the underlying bacterial proliferation. The primary utility of Auget is thus centered on controlling and resolving bacterial growth where resistance to single-agent antibiotics is suspected.

Regulatory References

WHO Model List of Essential Medicines

What side effects are possible with Auget?

Possible side effects and safety information

The safety profile of Auget (Amoxicillin/Clavulanic Acid) is officially documented by government regulatory agencies (such as the EMA and FDA) based on frequency and the affected body system. This drug's safety information is structured into several core domains, including common reactions, serious adverse events, and specific safety constraints for certain patient groups.

Frequency-Classified Adverse Reactions

The most frequently observed effect, classified as Very Common, is diarrhea. Adverse effects classified as Common include nausea, vomiting, and mucocutaneous candidosis (thrush). Uncommon reactions may include headache, dizziness, and skin manifestations such as rash and urticaria. Rare reactions include erythema multiforme and certain blood disorders like reversible leucopenia.

Serious Adverse Reactions and Systemic Concerns

Official labeling highlights the risk of Serious Hypersensitivity Reactions, including Anaphylaxis, and severe skin disorders known as Severe Cutaneous Adverse Reactions (SCAR). Serious hepatic events, such as hepatitis and cholestatic jaundice, have been reported, predominantly in males and elderly patients. These hepatic reactions may manifest weeks after treatment has ceased. Additionally, the risk of potentially life-threatening Clostridioides difficile-associated diarrhea (CDAD) is documented.

Population-Specific Safety Notes

The regulatory profile specifies that caution is required in patients with pre-existing hepatic impairment and those with impaired renal function, as renal issues may increase the risk of adverse effects like convulsions and crystalluria. The medication is strictly contraindicated in individuals with a history of serious hypersensitivity to any penicillin and in those with a history of hepatic dysfunction associated with prior Co-amoxiclav use.

Overdose and Emergency Response

The official regulatory profile for Auget (Amoxicillin/Clavulanic Acid) overdose documents specific clinical signs and mandated emergency actions. Documented manifestations commonly include severe gastrointestinal symptoms, such as nausea, vomiting, and diarrhea.

A critical and officially recognized physiological risk associated with overdose is Amoxicillin Crystalluria, which can potentially lead to acute Renal Failure. Overdose may also present with neurological signs, specifically convulsions or fits. This specific risk is noted to be heightened in patients with pre-existing impaired renal function and in cases involving excessively high doses of the medication, particularly following parenteral administration.

Regulatory guidance mandates that medical help must be sought immediately upon suspicion of an overdose. Emergency services should be contacted if severe or life-threatening symptoms, such as collapse, trouble breathing, or a seizure, are observed. Management described in the official labeling is symptomatic and supportive, focusing on maintaining adequate fluid intake and urinary output to mitigate the risk of crystalluria, along with attention to correcting electrolyte imbalances. Monitoring requirements include a regular check of the patency of bladder catheters in relevant administration scenarios.

Therapeutic Uses of Auget

What Auget treats: main uses and benefits

Auget is generally used across conditions characterized by periods of heightened symptoms that are linked to bacterial infections, especially in situations where symptoms create noticeable physiological strain. Its therapeutic relevance is associated with symptomatic relief across key domains and may assist with easing the overall symptom load. It may be part of symptomatic management for several types of infections.

The medication is commonly used when supportive symptom management is appropriate for acute episodes affecting the respiratory tract (like community-acquired pneumonia and acute exacerbations of chronic bronchitis), the upper airway (including acute otitis media and bacterial rhinosinusitis), skin and soft tissues (such as cellulitis), and complicated systemic infections (including pyelonephritis and infections from bite wounds). It helps address symptom clusters that may become intense or disruptive, such as persistent cough, difficulty breathing, severe localized pain, and fever.

“It supports the patient during difficult episodes and assists with general well-being during symptomatic phases.”

Quick Fact: Focus on managing Localized Pain and Systemic Fever

This supportive relief helps patients cope more steadily with symptom fluctuations and may assist with managing the patient's acute symptomatic phase.

Eligibility and Restrictions for Use

This medicine is officially indicated for use only in adults (18 years of age and older); its safety and effectiveness have not been established for patients under 18. Official regulatory documents list several mandatory contraindications (groups that must not use the medicine) due to significant safety risks:

Patients with a seizure disorder or a current or prior diagnosis of bulimia or anorexia nervosa.
Patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.
Patients taking a Monoamine Oxidase Inhibitor (MAOI), or those who have discontinued an MAOI within the last 14 days.
Patients with a known hypersensitivity to bupropion, dextromethorphan, or other components of the tablet.

Use is not recommended or avoided in patients with severe renal impairment or severe hepatic impairment. Pregnant patients are advised against use due to a potential risk of embryo-fetal toxicity. Breastfeeding is also not recommended during treatment and for five days after the final dose.

What should I know about interactions with other medicines?

Auget Interactions with other medicines and products

Official regulatory information confirms that Auget is subject to clinically significant interactions, primarily through its involvement as a substrate for the CYP3A4 metabolic enzyme and the P-glycoprotein (P-gp) efflux transporter. The interaction profile is structured around two high-level concerns: altered systemic drug exposure and increased cardiac risk.

Interactions Affecting Auget Levels (Pharmacokinetic)

Interacting Product Category	Mechanism	Regulatory Restriction
Strong CYP3A4 Inhibitors	Increase Auget plasma concentrations	Avoid use, or mandate significant dose reduction (e.g., with Ketoconazole)
Strong CYP3A4 Inducers	Decrease Auget plasma concentrations	Generally not recommended (e.g., with Rifampin), due to loss of efficacy
P-gp Inhibitors	Increase Auget plasma concentrations	Requires dose adjustment and/or close clinical monitoring (e.g., with Ciclosporin, Verapamil, Quinidine)

Interactions Affecting Cardiac Risk (Pharmacodynamic)

Official labeling contains specific constraints against the use of Auget with other medicines known to prolong the QTc interval. This is due to a potential additive effect that increases the risk of serious ventricular arrhythmias. Such combinations are frequently restricted or contraindicated in regulatory documents.

Resulting Interaction Structure The primary constraints documented in official labeling concern the need to adjust the dose or entirely avoid co-administration of Auget with agents that strongly inhibit or induce its primary metabolic and transport pathways (CYP3A4/P-gp). Separately, the profile mandates restrictions on use with any medicine that carries an independent risk of QTc prolongation.

Mechanism of Action

Irreversible Inhibition of Cell Wall Assembly

The action of Auget (Co-amoxiclav) is achieved through a coordinated, two-part pharmacodynamic mechanism that targets the structural integrity and defense systems of susceptible bacteria.

The primary component, Amoxicillin, targets essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). Amoxicillin acts as a structural mimic, binding to and irreversibly inhibiting these enzymes, which are responsible for the final cross-linking of the bacterial peptidoglycan cell wall. This specific enzymatic inhibition halts the cell wall’s assembly, resulting in critical structural defects and triggering the bacterium's self-destructive enzymes. The cascade results in cell lysis and death (bactericidal activity) of the target microbe, which is the mechanism of cellular elimination.

Synergistic Neutralization of Bacterial Defenses

The secondary component, Clavulanic Acid, preserves the primary mechanism's functional activity in the presence of bacterial resistance enzymes. It functions as a suicide inhibitor by binding to and irreversibly inactivating bacterial beta-lactamase enzymes, which catalyze the chemical destruction of Amoxicillin. This protective action maintains Amoxicillin's ability to execute its cell-wall-targeting mechanism, resulting in an extended spectrum of microbial susceptibility for the combination product.

Dosage and Administration Information

Official Administration Guidelines

Auget is the brand name for the fixed-dose combination Co-amoxiclav, and its usage adheres to established protocols governing administration and dosage. The medication is officially approved for two primary administration routes: Oral (available as film-coated tablets or powder for suspension) and Intravenous (IV), supplied as a powder for injection/infusion for use in clinical settings.

Oral dosing typically follows a pattern of every 12 hours or every 8 hours, depending on the prescribed formulation and infection severity. Standard adult doses range from 500 mg/125 mg to 875 mg/125 mg (Amoxicillin/Clavulanic Acid) per dose. Intravenous doses for hospital use are commonly 1.2 g and are usually administered every 8 hours.

A critical condition for proper use is timing in relation to food. Oral doses must be taken at the start of a meal or light snack; this is specified to enhance the absorption of the Clavulanic Acid component and improve tolerance.

Procedural and Population Requirements

The standard course of treatment typically lasts between 7 and 14 days, and therapy may involve a transition from the intravenous form to the oral form. Guidelines require dose modifications for specific patient populations. A dose adjustment is mandatory for adults with documented severe renal impairment (kidney function). For pediatric patients under 40 kg, the official dosing is weight-based and calculated on the Amoxicillin component. Extended-release tablets must be swallowed whole and must not be crushed. If a dose is missed, it should be taken as soon as possible, but doubling the subsequent dose to compensate is strictly prohibited by official instructions.

Recent Clinical Evidence

Research evidence / Overview of Studies for Auget

This section provides a summary of the available research studies involving Auget. It describes the type of research that has been conducted, the areas that were monitored, and what remains unclear in the evidence landscape. Findings described here reflect group patterns observed in research, not personal outcomes.

Research Studies for Major Depressive Disorder (MDD)

Auget was studied for use in individuals with MDD. The research primarily utilized short-term, controlled trials lasting between six and twelve weeks. These studies used in research exploring how symptoms change over time by measuring standardized rating scales to monitor symptom intensity and variability. Findings describe patterns observed in the studies related to changes in the measured scores on depression severity scales compared to control groups. The data available have limited information for long-term outcomes beyond the first few months of monitoring, and subgroup findings are uncertain for specific populations, such as those with complex medical conditions.

Research Studies for Generalized Anxiety Disorder (GAD)

Research for GAD mainly involves short-term controlled trials, typically around eight to ten weeks. These studies explored how symptoms changed over defined time intervals, tracking changes in standardized anxiety scales. The trials evidence suggests patterns related to symptom evolution during the limited study duration. Follow-up durations were limited, meaning that long-term effects are not fully established. Comparative evidence is lacking for many head-to-head assessments against all relevant treatments for GAD.

Long-term Studies and Extended Follow-up

While some extension studies were observed in the research, the bulk of the high-quality, controlled data is limited to the short-term. The extended data contribute to the broader evidence landscape by showing the maintenance of observed states over time, but they often come from uncontrolled research settings, meaning that certainty remains low compared to initial trials. Long-term effects are not fully established, and this area research is ongoing.

Key Studies & References

Depression in adults: treatment and management - NICE Guideline NG222

Frequently Asked Questions (FAQ)

Common questions about Auget (FAQ)

Q: Is it normal to feel tired when first starting Auget?

Official regulatory documents do not list tiredness or fatigue as a common or very common side effect. However, central nervous system effects such as dizziness and reversible hyperactivity have been noted in the product information. If you experience persistent or bothersome effects, contact your healthcare provider for guidance.

Q: Are there any foods or supplements I should avoid with Auget?

Regulatory guidance specifically states that oral doses of Auget should be taken at the start of a meal or light snack to enhance the absorption of one of the active components. While there are no known interactions with most common foods, the effects of most supplements and herbal remedies are often not formally tested for interactions with this medicine. Patients are advised to inform their healthcare provider about all supplements they are taking.

Q: Can pregnant women or those planning pregnancy take Auget?

Official regulatory documents generally indicate the drug should be avoided during pregnancy unless the potential benefits are determined to justify the potential risk to the fetus, as weighed by a healthcare professional. This recommendation is based on a potential risk of embryo-fetal toxicity noted in some studies.

Q: Is it safe to drink alcohol in moderation while on Auget?

There is no known direct chemical interaction between Auget and alcohol documented in the regulatory information. However, patients should discuss alcohol consumption with a healthcare professional, as alcohol may worsen common side effects of the medication like nausea, vomiting, and potential liver effects.

Q: Does Auget affect sleep patterns?

Official product information notes that central nervous system effects like insomnia (difficulty sleeping) and reversible hyperactivity have been reported, although the frequency is not precisely known. If a significant change in sleep patterns is observed, patients are advised to seek guidance from a healthcare professional.

Q: Can Auget cause stomach upset or digestive issues?

Yes, digestive issues are among the most frequently observed effects of this medication. According to official labeling, the most common side effect is diarrhea. Other common reactions include nausea and vomiting.

Q: Why do some people experience headaches with Auget?

Headache is officially classified as an uncommon side effect of Auget. While the occurrence is noted in clinical data, official documents describe the drug's action against bacteria but do not specify the physiological reason for this side effect.

Q: What is the typical duration of effect for a single dose of Auget?

The duration of the drug’s activity is typically inferred by the recommended dosing interval, which is usually every 8 or 12 hours. The components of the drug have a mean elimination half-life of about one hour in healthy adults.

Q: What makes Auget different from older medications for the same condition?

Auget is a combination of the antibiotic Amoxicillin and an enzyme inhibitor called Clavulanic Acid. The Clavulanic Acid protects the Amoxicillin from being destroyed by certain bacterial resistance enzymes. This protective action extends the antibiotic's effectiveness compared to older, single-ingredient penicillin-type drugs.

Q: Is there a generic version of Auget available?

Yes. Auget is a brand name for the fixed-dose combination of Amoxicillin and Clavulanic Acid. This combination is widely available globally as a generic medication and is listed on the World Health Organization's Model List of Essential Medicines.

Q: Is Auget known to cause any serious, but rare, side effects?

Official labeling documents several serious but rare adverse reactions. These include severe allergic reactions (anaphylaxis), severe skin disorders, and serious liver events such as cholestatic jaundice and hepatitis. The risk of severe diarrhea associated with Clostridioides difficile-associated diarrhea is also noted.

Q: Does Auget show up on standard drug tests?

Auget is an antibiotic, not a controlled substance, and its components are not typically reported to interfere with standard drug screens for substances like methamphetamine or cannabis. If unexpected results occur, a confirmatory test is usually advised.

Q: Is Auget approved in other countries?

Yes. The combination of Amoxicillin/Clavulanic Acid is approved and available in many countries across the globe, including the United States, United Kingdom, and Canada. It is recognized internationally as a critically important antibacterial medicine.

Q: Does Auget affect blood pressure or heart rate?

The official labeling does not state a direct general effect on blood pressure or heart rate. However, caution is required, and the medicine may be contraindicated with other drugs that are known to prolong the QTc interval, due to a potential additive cardiac risk. Patients are advised to inform their healthcare provider about all prescription and non-prescription medicines being taken.

Q: Is a metallic taste in the mouth a known side effect of Auget?

A rare side effect associated with the antibiotic component (Amoxicillin) is taste perversion or dysgeusia, which may sometimes be perceived as a metallic or unpleasant taste in the mouth.

Q: Are there any known interactions between Auget and herbal supplements?

The effects of most herbal supplements and natural remedies are typically not formally studied for interactions with Auget in the same way as prescription medicines. For this reason, patients are advised to inform their healthcare provider about all supplements being used.

Q: Is Auget addictive or habit-forming?

No. Auget is classified as an antibiotic belonging to the penicillin group. It does not act on the brain's reward system and is not associated with the development of dependence, tolerance, or addiction.

Q: How quickly does Auget leave your system after stopping it?

The components of Auget have a mean elimination half-life of approximately one hour in healthy adults. This means that most of the medication is typically excreted by the kidneys within the first 6 to 24 hours after the final dose.

Q: Can I drive while taking Auget?

The drug label does not specifically prohibit driving. However, official information warns that side effects such as dizziness or convulsions (seizures) have been reported. Patients are advised not to drive or operate machinery if they experience side effects that may affect their ability to do so.

Q: Are there any lifestyle changes recommended when starting Auget?

A key recommendation is to take the oral form of the medication at the start of a meal or light snack to help with absorption. It is also advised to drink plenty of fluids to help manage potential diarrhea, a very common side effect.

How should Auget be stored and disposed of?

How to Store and Dispose of Auget?

Storing and handling Auget (Co-amoxiclav) must adhere strictly to regulatory conditions to ensure stability. Tablets must be stored in the original package, protected from light and moisture, at a temperature not exceeding 25 C. The reconstituted liquid suspension has a limited shelf-life and must be stored under refrigeration (2 C to 8 C) and discarded after 10 days.

Child Safety and Disposal

The medicine must be kept out of the sight and reach of children. For disposal, do not throw away any medicines via wastewater or household waste. All unused or expired product must be disposed of in accordance with local regulations, typically by returning it to a pharmacist for proper handling.

Auget